Press Release September 15, 2021

AbCellera Acquires TetraGenetics

The Life Sciences team advised AbCellera (Nasdaq: ABCL) on its acquisition of TetraGenetics, Inc.

AbCellera is a technology company with a centralized operating system for next-generation antibody discovery.

TetraGenetics is a biotechnology company with a proprietary platform for generating recombinant human ion channels and other transmembrane proteins.

Integrating TetraGenetics’ capabilities into AbCellera’s technology stack provides an optimized protein source for AbCellera’s antibody discovery. 

The all-cash transaction includes an upfront payment, the potential for payments based on the achievement of technical milestones, and additional development and commercial milestone payments related to successfully developed therapeutics.

The Goodwin team was led by Deepa M. Rich, Sam Zucker, and Shoaib Ghias, and included Carolyn Nguyen, Pooja Sudarshan, William Newman, Margaret Beale-Wirsing, Alex Varond, Sarah Wicks, Roger Cohen, Heath Roosevelt Ingram, Andrew Hess, Daniel Karelitz, Crescent Moran Chasteen, Emilie Pfister, Shane Albright, Simone Waterbury, Ortal Ben Aharon, April Sun, Nori Lu, Grace Wirth, Garrett Gaughan, Carzon Zheng, Jacqueline Klosek, Lee Douthitt, and Vanessa Quiban-Tolentino.

Goodwin also advised AbCellera on its $555.5 million IPO.

For more details on the acquisition, read the press release and articles in Endpoints, The Pharma Letter, and Seeking Alpha.